This guideline has been produced by the National Osteoporosis Guideline Group (NOGG) and offers updated guidance on identifying who is at risk of osteoporosis, assessing the risk of having a fracture, actions on lifestyle and diet, and which drugs should be prescribed and when. It is intended for all healthcare professionals involved in the management of osteoporosis; this includes primary care practitioners and relevant specialists in secondary care. It is accredited by NICE and is produced with the support of organisations including the National Osteoporosis Society, the Bone Research Society, the British Geriatric Society and the Royal College of General Practitioners. This guideline updates those previously developed by the Royal College of Physicians (RCP 1999, 2000) and the National Osteoporosis Guideline Group (2013).

This information leaflet is written for patients and the public. It provides a simple, plain language summary of the Clinical Guideline written by the UK National Osteoporosis Guideline Group (NOGG). It tells your patients how the Guideline affects them, what it says, and who uses it.

This guidance is an update to the 2011 Scottish Dental Clinical Effectiveness Programme (SDCEP) publication ‘Oral Health Management of Patients Prescribed Bisphosphonates’. It provides clear and practical advice for dentists in primary care on how to provide care for patients prescribed bisphosphonates. The guidance is also of relevance to prescribers and dispensers of bisphosphonates.

Guidance for the Management of Breast Cancer Treatment-Induced Bone Loss: A consensus position statement from a UK Expert Group

Reviewed and supported by the National Osteoporosis Society, the National Cancer Research Institute, Breast Cancer Study Group and the International Osteoporosis Foundation.

A group of UK experts have drawn up a guidance report for the management of breast-cancer induced bone loss. The new report, which was created after a full review of available literature, has been endorsed by The National Osteoporosis Society. The full guidance document and two treatment algorithms, one for premenopausal women and one for postmenopausal women, is available